Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.
Several other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $22.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, May 1st. Mizuho lowered their price objective on shares of Marinus Pharmaceuticals from $5.00 to $1.70 and set a “neutral” rating on the stock in a research report on Tuesday, July 23rd. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $3.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, July 25th. Finally, Zacks Investment Research raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $11.39.
NASDAQ MRNS traded up $0.06 on Thursday, hitting $1.10. 436,254 shares of the stock were exchanged, compared to its average volume of 1,750,340. Marinus Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $10.54. The business’s 50-day moving average price is $3.54.
In other Marinus Pharmaceuticals news, CFO Edward F. Smith sold 24,211 shares of Marinus Pharmaceuticals stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $5.03, for a total transaction of $121,781.33. Following the completion of the sale, the chief financial officer now owns 20,097 shares of the company’s stock, valued at approximately $101,087.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.10% of the company’s stock.
Several large investors have recently modified their holdings of MRNS. BNP Paribas Arbitrage SA boosted its stake in shares of Marinus Pharmaceuticals by 1,465.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,047 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 9,405 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at $69,000. Gabelli Funds LLC lifted its stake in shares of Marinus Pharmaceuticals by 58.8% in the 1st quarter. Gabelli Funds LLC now owns 27,000 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 10,000 shares during the last quarter. Bailard Inc. acquired a new stake in shares of Marinus Pharmaceuticals in the 1st quarter valued at $138,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at $146,000. 63.34% of the stock is owned by institutional investors.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Further Reading: What is Depreciation?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.